Management of endocrine disease: Osteogenesis imperfecta: An update on clinical features and therapies
R Marom, BM Rabenhorst… - European journal of …, 2020 - academic.oup.com
Osteogenesis imperfecta (OI) is an inherited skeletal dysplasia characterized by bone
fragility and skeletal deformities. While the majority of cases are associated with pathogenic …
fragility and skeletal deformities. While the majority of cases are associated with pathogenic …
Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types
Osteogenesis imperfecta (OI) is a phenotypically and genetically heterogeneous skeletal
dysplasia characterized by bone fragility, growth deficiency, and skeletal deformity …
dysplasia characterized by bone fragility, growth deficiency, and skeletal deformity …
[HTML][HTML] LRRc17 controls BMSC senescence via mitophagy and inhibits the therapeutic effect of BMSCs on ovariectomy-induced bone loss
F Liu, Y Yuan, L Bai, L Yuan, L Li, J Liu, Y Chen, Y Lu… - Redox biology, 2021 - Elsevier
Senescence of bone marrow-derived mesenchymal stem cells (BMSCs) has been widely
reported to be closely correlated with aging-related diseases, including osteoporosis (OP) …
reported to be closely correlated with aging-related diseases, including osteoporosis (OP) …
Heterogeneity of murine periosteum progenitors involved in fracture healing
The periosteum is the major source of cells involved in fracture healing. We sought to
characterize progenitor cells and their contribution to bone fracture healing. The periosteum …
characterize progenitor cells and their contribution to bone fracture healing. The periosteum …
Osteoporosis and the potential of cell-based therapeutic strategies
I Macías, N Alcorta-Sevillano, CI Rodríguez… - International journal of …, 2020 - mdpi.com
Osteoporosis, the most common chronic metabolic bone disease, is characterized by low
bone mass and increased bone fragility. Nowadays more than 200 million individuals are …
bone mass and increased bone fragility. Nowadays more than 200 million individuals are …
Mesenchymal stem cells in the treatment of osteogenesis imperfecta
E Lang, JA Semon - Cell Regeneration, 2023 - Springer
Osteogenesis imperfecta (OI) is a disease caused by mutations in different genes resulting
in mild, severe, or lethal forms. With no cure, researchers have investigated the use of cell …
in mild, severe, or lethal forms. With no cure, researchers have investigated the use of cell …
PDGF inhibits BMP2-induced bone healing
Bone regeneration depends on a pool of bone/cartilage stem/progenitor cells and signaling
mechanisms regulating their differentiation. Using in vitro approach, we have shown that …
mechanisms regulating their differentiation. Using in vitro approach, we have shown that …
Inhibition of CGRP signaling impairs fracture healing in mice
Calcitonin gene‐related peptide (CGRP) is a neuropeptide produced by sensory nerves and
functions as a pain sensor. It acts by binding to the calcitonin‐like receptor (CLR, protein; …
functions as a pain sensor. It acts by binding to the calcitonin‐like receptor (CLR, protein; …
Modulation of Notch1 signaling regulates bone fracture healing
Fracture healing involves interactions of different cell types, driven by various growth factors,
and signaling cascades. Periosteal mesenchymal progenitor cells give rise to the majority of …
and signaling cascades. Periosteal mesenchymal progenitor cells give rise to the majority of …
Safety and efficacy of Wharton's jelly-derived mesenchymal stem cells with teriparatide for osteoporotic vertebral fractures: A phase I/IIa study
Osteoporotic vertebral compression fractures (OVCFs) are serious health problems. We
conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety …
conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety …